NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
OTC · FNCH · USD
Stock price, earnings
Quote as of Aug 5, 2026, 07:47 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Finch Therapeutics Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 36.65% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Finch Therapeutics Group, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Finch Therapeutics is a microbiome technology company with a portfolio of intellectual property and microbiome assets. The company is now focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations after winding down development efforts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$38.91-$1.58 (-3.9%)
Edgewise Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.79% below the high.
$1.10+$0.04 (+3.77%)
Werewolf Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.03% below the high.
$0.84-$0.01 (-1.17%)
Connect Biopharma Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 78.13% below the high.
$4.05-$0.15 (-3.57%)
ImageneBio Inc’s quoted price sits in the lower half of its reported 52-week range, 54.75% below the high.
$0.62-$0.02 (-3.84%)
Biomea Fusion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.2% below the high.
$0.37-$0.02 (-5.95%)
Pasithea Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 82.06% below the high.
$4.15+$0.04 (+0.97%)
Quoin Pharmaceuticals, Ltd.’s quoted price sits in the lower half of its reported 52-week range, 82.34% below the high.
